

SparingVision to Present at the Ophthalmology Innovation Summit (OIS) in Chicago on July 25th, 2019 during the American Society of Retinal Specialists (ASRS) meeting

Paris, July 25, 2019 - SparingVision, a biotechnology company specializing in the research and development of innovative therapies for treating hereditary retinal degenerative diseases such as retinitis pigmentosa, has today announced that Florence Allouche, President, provided a Company update, including the latest news in the development of SPVN06 breakthrough technology gene independent for the treatment of Retinitis Pigmentosa, during the session "Exciting Research Projects Funded by the Foundation Fighting Blindness" on July 25th, 2019 in Chicago.

The Ophthalmology Innovation Summit (OIS) is the leading meeting bringing together researchers, innovators, industry, and investors showcasing the latest progress and innovations in Ophthalmology. For the second year, Foundation Fighting Blindness have partnered with OIS@ASRS to showcase at the OIS during the American Society of Retinal Specialists (ASRS) meeting in Chicago on Thursday, July 25th, the great innovations happening in the IRD space.

"We are very proud to share our preclinical datas among this prestigious summit. Professor José Sahel, scientific co-founder of the company, founder and director of the Vision Institute in Paris, FR, Chairman of the Department of Ophthalmology, University of Pittsburgh, US, did this presentation" explains Florence Allouche, President of SparingVision. We are starting the production of our clinical batches to initiate the first clinical trials in Europe and the United States in 2020".

About SparingVision

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects 40,000 people in France and nearly 2 million worldwide. SparingVision is a spin-off of the Paris Vision Institute. Bpifrance, Foundation Fighting Blindness (US) and Voir & Entendre Foundation invested €15.5 million in the company. SparingVision was laureate and Grand Prize of i-Lab 2017, the National Contest for the Creation of Innovative Companies, and is part of the first selection of companies of Hub Health Tech launched by Bpifrance in December 2017. Florence Allouche, President of SparingVision, has won the Mercuries Entrepreneurs Prize and the Women Trajectory's award from HEC Paris and was elected "Woman of the Year 2017" by the financial magazine La Tribune.

www.sparingvision.com

Contacts:

Florence Allouche

Pharm D. MBA

President SparingVision,

+33 1 43 46 20 60

fag@sparingvision.com

Florence Portejoie,

FP2COM

+ 33 6 07 76 82 83

fportejoie@fp2com.fr